These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

565 related items for PubMed ID: 10871828

  • 1. The Danish National Project of interferon-beta treatment in relapsing-remitting multiple sclerosis. The Danish Multiple Sclerosis Group.
    Koch-Henriksen N, Sørensen PS.
    Mult Scler; 2000 Jun; 6(3):172-5. PubMed ID: 10871828
    [Abstract] [Full Text] [Related]

  • 2. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial.
    Mikol DD, Barkhof F, Chang P, Coyle PK, Jeffery DR, Schwid SR, Stubinski B, Uitdehaag B, REGARD study group.
    Lancet Neurol; 2008 Oct; 7(10):903-14. PubMed ID: 18789766
    [Abstract] [Full Text] [Related]

  • 3. Interferon-beta-1b: a review of its use in relapsing-remitting and secondary progressive multiple sclerosis.
    McCormack PL, Scott LJ.
    CNS Drugs; 2004 Oct; 18(8):521-46. PubMed ID: 15182221
    [Abstract] [Full Text] [Related]

  • 4. Efficacy and tolerability of intramuscular interferon beta-1a compared with subcutaneous interferon beta-1a in relapsing MS: results from PROOF.
    Minagara A, Murray TJ, PROOF Study Investigators.
    Curr Med Res Opin; 2008 Apr; 24(4):1049-55. PubMed ID: 18315940
    [Abstract] [Full Text] [Related]

  • 5. Spotlight on Interferon-beta-1b in relapsing-remitting and secondary progressive multiple sclerosis.
    McCormack PL, Scott LJ.
    BioDrugs; 2004 Apr; 18(5):343-7. PubMed ID: 15377176
    [Abstract] [Full Text] [Related]

  • 6. Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis.
    La Mantia L, Di Pietrantonj C, Rovaris M, Rigon G, Frau S, Berardo F, Gandini A, Longobardi A, Weinstock-Guttman B, Vaona A.
    Cochrane Database Syst Rev; 2014 Jul 26; (7):CD009333. PubMed ID: 25062935
    [Abstract] [Full Text] [Related]

  • 7. The clinical effect of neutralizing antibodies against interferon-beta is independent of the type of interferon-beta used for patients with relapsing-remitting multiple sclerosis.
    Koch-Henriksen N, Sorensen PS, Bendtzen K, Flachs EM.
    Mult Scler; 2009 May 26; 15(5):601-5. PubMed ID: 19299439
    [Abstract] [Full Text] [Related]

  • 8. NORdic trial of oral Methylprednisolone as add-on therapy to Interferon beta-1a for treatment of relapsing-remitting Multiple Sclerosis (NORMIMS study): a randomised, placebo-controlled trial.
    Sorensen PS, Mellgren SI, Svenningsson A, Elovaara I, Frederiksen JL, Beiske AG, Myhr KM, Søgaard LV, Olsen IC, Sandberg-Wollheim M.
    Lancet Neurol; 2009 Jun 26; 8(6):519-29. PubMed ID: 19409854
    [Abstract] [Full Text] [Related]

  • 9. Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study.
    Khatri B, Barkhof F, Comi G, Hartung HP, Kappos L, Montalban X, Pelletier J, Stites T, Wu S, Holdbrook F, Zhang-Auberson L, Francis G, Cohen JA, TRANSFORMS Study Group.
    Lancet Neurol; 2011 Jun 26; 10(6):520-9. PubMed ID: 21571593
    [Abstract] [Full Text] [Related]

  • 10. Subcutaneous recombinant interferon-beta-1a (Rebif): a review of its use in relapsing-remitting multiple sclerosis.
    Murdoch D, Lyseng-Williamson KA.
    Drugs; 2005 Jun 26; 65(9):1295-312. PubMed ID: 15916455
    [Abstract] [Full Text] [Related]

  • 11. Simvastatin treatment in patients with relapsing-remitting multiple sclerosis receiving interferon beta 1a: a double-blind randomized controlled trial.
    Togha M, Karvigh SA, Nabavi M, Moghadam NB, Harirchian MH, Sahraian MA, Enzevaei A, Nourian A, Ghanaati H, Firouznia K, Jannati A, Shekiba M.
    Mult Scler; 2010 Jul 26; 16(7):848-54. PubMed ID: 20488825
    [Abstract] [Full Text] [Related]

  • 12. The combination of cyclophosphamide plus interferon beta as rescue therapy could be used to treat relapsing-remitting multiple sclerosis patients-- twenty-four months follow-up.
    Reggio E, Nicoletti A, Fiorilla T, Politi G, Reggio A, Patti F.
    J Neurol; 2005 Oct 26; 252(10):1255-61. PubMed ID: 15940386
    [Abstract] [Full Text] [Related]

  • 13. Oral interferon beta-1a in relapsing-remitting multiple sclerosis: a double-blind randomized study.
    Polman C, Barkhof F, Kappos L, Pozzilli C, Sandbrink R, Dahlke F, Jakobs P, Lorenz A, European Oral Interferon Beta-1a in Relapsing-Remitting MS Study Group.
    Mult Scler; 2003 Aug 26; 9(4):342-8. PubMed ID: 12926838
    [Abstract] [Full Text] [Related]

  • 14. Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis.
    Kappos L, Wiendl H, Selmaj K, Arnold DL, Havrdova E, Boyko A, Kaufman M, Rose J, Greenberg S, Sweetser M, Riester K, O'Neill G, Elkins J.
    N Engl J Med; 2015 Oct 08; 373(15):1418-28. PubMed ID: 26444729
    [Abstract] [Full Text] [Related]

  • 15. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial.
    Cohen JA, Coles AJ, Arnold DL, Confavreux C, Fox EJ, Hartung HP, Havrdova E, Selmaj KW, Weiner HL, Fisher E, Brinar VV, Giovannoni G, Stojanovic M, Ertik BI, Lake SL, Margolin DH, Panzara MA, Compston DA, CARE-MS I investigators.
    Lancet; 2012 Nov 24; 380(9856):1819-28. PubMed ID: 23122652
    [Abstract] [Full Text] [Related]

  • 16. Pegylated interferon β-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study.
    Calabresi PA, Kieseier BC, Arnold DL, Balcer LJ, Boyko A, Pelletier J, Liu S, Zhu Y, Seddighzadeh A, Hung S, Deykin A, ADVANCE Study Investigators.
    Lancet Neurol; 2014 Jul 24; 13(7):657-65. PubMed ID: 24794721
    [Abstract] [Full Text] [Related]

  • 17. Alemtuzumab versus interferon β-1a in early relapsing-remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomes.
    Coles AJ, Fox E, Vladic A, Gazda SK, Brinar V, Selmaj KW, Bass AD, Wynn DR, Margolin DH, Lake SL, Moran S, Palmer J, Smith MS, Compston DA.
    Lancet Neurol; 2011 Apr 24; 10(4):338-48. PubMed ID: 21397567
    [Abstract] [Full Text] [Related]

  • 18. Interferon beta in relapsing-remitting multiple sclerosis. An eight years experience in a specialist multiple sclerosis centre.
    Río J, Tintoré M, Nos C, Téllez N, Galán I, Montalban X.
    J Neurol; 2005 Jul 24; 252(7):795-800. PubMed ID: 15772741
    [Abstract] [Full Text] [Related]

  • 19. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN).
    Durelli L, Verdun E, Barbero P, Bergui M, Versino E, Ghezzi A, Montanari E, Zaffaroni M, Independent Comparison of Interferon (INCOMIN) Trial Study Group.
    Lancet; 2002 Apr 27; 359(9316):1453-60. PubMed ID: 11988242
    [Abstract] [Full Text] [Related]

  • 20. MRI brain volume changes in relapsing-remitting multiple sclerosis patients treated with interferon beta-1a.
    Gasperini C, Paolillo A, Giugni E, Galgani S, Bagnato F, Mainero C, Onesti E, Bastianello S, Pozzilli C.
    Mult Scler; 2002 Apr 27; 8(2):119-23. PubMed ID: 11990868
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.